Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970

742.12 +3.40 +0.46%

Live - 5344 symbols - heartbeat 562s ago · 2026-10-08 05:13

Pre-market 742.00 -0.02%

After-hours 742.12 0.00%

Overnight 741.93 -0.03%

Market cap: 76.40B
P/E (TTM): 18.36
P/B: 2.41
EPS: 41.48
Div yield: 0.49%
52W pos: 63%

Reader sentiment Are you bullish or bearish on REGN?

Anonymous reader poll. Unscientific, not investment advice.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Founded: 1988
CEO: Dr. Leonard S. Schleifer,M.D.,PhD
Employees: 15,410
Headquarters: Tarrytown, New York, United States of America
Fiscal year end: 12-31
Website: regeneron.com

Company profile

Exchange: US
Symbol: REGN
Market-cap rank: #285
Listing date: 1970-01-01
Market cap: 76.40B
Float cap: 73.43B
Shares out: 102.95M
Float shares: 98.95M

Sectors & themes

Biotechnology ARK Portfolio Infectious Disease Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.